Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Hemostemix Inc
<< Previous
 Bullboard Posts
User Avatar Image
(51)
•••
Post by sdhakaon Jun 04, 2024 2:35pm
99 Views
Post# 36071689

Hemostemix Announces Partnership and Funding

Hemostemix Announces Partnership and Funding

Hemostemix Announces Partnership and Funding for ACP-01 Manufacturing


Hemostemix Inc. (HEM) announced a strategic manufacturing partnership with CytoImmune Therapeutics, a private company specializing in clinical manufacturing for biotech firms.


This collaboration involves a Letter of Intent (LOI) to jointly manufacture Hemostemix's lead product, ACP-01. The goal is to provide this investigational treatment to patients with critical needs on a compassionate-use basis.


Compassionate-use programs allow access to unapproved treatments for patients with life-threatening conditions who have no other options.
Read more on this update for free : https://www.researchfrc.com/content/analyst-ideas/post/96/data-backs-our-rate-cut-predictions-time-to-revisit-lithium-stocks

 

*FRC provides issuer-paid coverage.

*Past performance is not indicative of future results.


<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities